Pinsent Masons advises UCL on £300m sustainability bond

Multinational law firm Pinsent Masons has advised University College London (UCL) on its debut issue of £300m 1.625% sustainability bonds due 2061 – the first publicly listed sustainability bonds in the higher education sector.

The bonds are rated Aa3 by Moody’s and were priced at a spread of 0.50% over the relevant reference gilt.

UCL will allocate an amount equivalent to the net proceeds of the bonds to the acquisition, financing, or refinancing of new or existing eligible sustainable projects in accordance with its sustainability finance framework.

The team at Pinsent Masons was led by debt capital markets and sustainability bond finance expert Alexis Hayworth, with governance advice from partner and higher education expert Gayle Ditchburn and assistance from higher education finance solicitor Katy McBride.

Commenting on this, Alexis Hayworth said: “We are delighted to have advised on UCL’s debut sustainability bond, which showcases the strength and depth of Pinsent Masons’ higher education finance practice. It is great that we are seeing higher education providers positively embrace sustainability products and we anticipate this trend continuing within the sector given the focus on the environment across campuses and the momentum of ESG (Environmental, Social and Governance) as an asset class in the market this year.”

Commenting on the issue, Dr Michael Spence, UCL President & Provost, said: “We are delighted by the success of this issue, and by the strong support shown by investors in UCL’s history and future. I am particularly proud that this is the sector’s first Sustainability Bond. It demonstrates our deep commitment to sustainability as an organisation and to addressing the global impact of climate change through our world-leading research.”

Latham Advises Unicredit on the Issuance of US$2 Billion in Senior Notes

UniCredit S.p.A. has successfully issued US$1 billion of Fixed to Fixed Rate Senior Preferred Notes, with a 6 year maturity and a call after 5 years, and US$1 billion of Fixed to Fixed Rate Senior Preferred Notes, with a 11 year maturity and a call after 10 years, targeted to institutional investors under 144A/Reg S for a total amount of US$2 billion. The transaction was completed under UniCredit’s US$30 billion US Global Medium Term Note Programme.

BofA Securities, Citi, Goldman Sachs International, J.P. Morgan, Morgan Stanley, TD Securities, and UniCredit acted as Joint Bookrunners for the Notes offering.

Latham & Watkins advised UniCredit S.p.A. in the transaction with a team led by London and Milan partner Ryan Benedict, with Milan partner Antonio Coletti and associates Giorgio Thomson Ignazzi, Marco Bonasso, and Marta Carini. Advice was also provided on US tax matters by New York partners Jocelyn Noll and Aaron Bernstein.

Latham & Watkins Advises on Ukraine’s US$1.25 Billion Bond

Latham & Watkins advised the joint lead managers and bookrunners on Ukraine’s successful pricing of its new US$1.25 billion notes due 2029 in international capital markets. The issuance was priced at 6.875% annual yield. The proceeds will be used for general budgetary purposes.

Latham continues to be the market leader in Ukrainian capital markets where it regularly acts for issuers and underwriters on a variety of offerings.

Latham’s deal team was led by corporate partners David Stewart and Manoj Tulsiani, with associates Harrison Armstrong, Amina Tsatiashvili, and Clive Wong. Advice was also provided by London litigation partner Oliver Browne.

About Latham & Watkins

Latham & Watkins LLP is an American law firm founded in 1934 in Los Angeles, California. In 2007, Latham became the first American law firm to surpass $2 billion in annual revenue and then, in 2018, it became the first American law firm to surpass $3 billion in annual revenue as well.

Baker McKenzie Advises Mytheresa in Approximately $407mn IPO

Baker McKenzie advised MYT Netherlands Parent B.V., the parent company of luxury e-commerce platform Mytheresa, in its approximately USD 407 million initial public offering of American Depositary Shares (ADSs). Mytheresa’s ADSs now trade on the New York Stock Exchange under the symbol “MYTE.”

The Baker McKenzie team included Roger Bivans, Chris Bartoli, Leif King, Eric Mattingly, Jamie Nix, Jeremy Poore, Derek Liu, Tom Asmar, Jonathan Martin, Robin Chesler, Christoph Wolf, Bernhard Trappehl, Kim Tan, Rebecca Kuijpers-Zimmerman, Ulrich Weidemann, Denise Ozmis and Willem Treuren, and numerous other team members in the United States, Netherlands, Germany and other countries.

About Baker McKenzie

Baker McKenzie is a transactional powerhouse with over 2,500 deal lawyers and expertise in over 46 countries. Our strong global reputation for both issuer and underwriter counsel is based on our ability to successfully navigate the highly complex mix of legal system and cultures in complex cross-border and domestic equity and debt offerings.

Kirkland Advises EQT on Expanded Partnership in IVC Evidensia

Kirkland & Ellis is advising EQT Private Equity on the additional investment and renewed long-term commitment in IVC Evidensia. As part of its long-term commitment to IVC, Kirkland advised EQT Private Equity in making a substantial investment through its EQT IX fund; Silver Lake is making a new substantial minority investment in IVC; Nestlé is also increasing its minority stake in IVC. The aggregated new investment from the expanded partnership transaction totals €3.5 billion and values IVC at an enterprise value of approximately €12.3 billion.

Headquartered in Bristol, UK, IVC is a leading veterinary services provider with a network of more than 1,500 clinics and hospitals and approximately 22,000 employees across Europe.

The Kirkland team was led by transactional partners Roger Johnson, David Holdsworth, Tom Bartram, Andreas Philipson and associate Irfan Ahmed.

Read EQT’s press release

Dentons advises Yonsung Group on acquisition of Arevipharma

Global law firm Dentons has advised the South Korean Yonsung Group on its acquisition of German-based pharmaceutical manufacturer Arevipharma. Through this transaction, the parties will expand and internationalise Arevipharma’s active ingredient business and innovate and invest in its Radebeul production site. The two companies also intend to benefit from synergies between Yonsung’s research-centred and long-term oriented business philosophy and Arevipharma’s established industrial network through the merger. The parties have agreed not to disclose the purchase price.

Yonsung Fine Chemicals was founded in 2000 as spin-off of Sungkyunkwan University in Seoul. The company is one of the world’s leading suppliers of Prostaglandin products and is focused on highly potent substances. In addition, the company has also started to develop its own finished medicinal products. Over the last three years, Yonsung group has more than doubled in revenue through proprietary development projects and patents, and in 2020, it achieved a turnover of more than US$50 million.

Arevipharma is a medium-sized manufacturer of generic and originator active pharmaceutical ingredients (API) and intermediates, which operates from a production site in Radebeul near Dresden. The product portfolio currently comprises more than 30 active pharmaceutical ingredients for various therapeutical areas in human and veterinary medicine.

A Dentons team from Munich, Frankfurt and Berlin advised Yonsung on all legal aspects of the transaction, including foreign trade in the healthcare sector, which has been complicated by the COVID-19 pandemic. Lead partner Thomas Strassner and his team regularly advise on transactions and venture capital financings in the healthcare sector.